Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03340506 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy sites: 34 to 35Secondary endpoints: details revised at 1 of 1 entry · Eligibility criteria expanded, about 5 wordsShow 2 more changesShow less
Secondary endpoints: details revised at 1 of 1 entry
Eligibility criteria expanded, about 5 words
MinorStudy sites: 33 to 34v49
MinorSite details revised at 2 of 33 sitesv48
Show 8 earlier versionsHide 8 earlier versions
MinorSite details revised at 3 of 33 sitesv47
MinorStudy sites: 32 to 33v46
MinorStudy sites: 31 to 32v45
MinorStart date: Dec 28, 2017 to Jan 26, 2018Study sites revised (31)v44Show 1 more changeShow less
NotablePrimary completion pushed from Dec 18, 2029 to Dec 28, 2032Completion pushed from Dec 28, 2030 to Dec 28, 2032 · Site details revised at 3 of 28 sitesv39Show 2 more changesShow less
Completion pushed from Dec 28, 2030 to Dec 28, 2032
Site details revised at 3 of 28 sites
MinorStudy sites: 27 to 28v38
NotablePrimary completion date: Dec 20, 2027 to Dec 18, 2029Completion date: Dec 21, 2027 to Dec 28, 2030 · Site details revised at 4 of 27 sitesv37Show 2 more changesShow less
NotablePrimary completion date: May 30, 2023 to Dec 20, 2027Study sites: 12 to 15 · Completion date: May 30, 2023 to Dec 21, 2027v15Show 2 more changesShow less
Study sites: 12 to 15
Completion date: May 30, 2023 to Dec 21, 2027
MinorSite details revised at 1 of 12 sitesv14
MinorStudy sites: 11 to 12v13
MinorRe-verified, no change to tracked fieldsv12
MinorPrimary and study completion dates: Jul 17, 2023 to May 30, 2023v11
MinorSite contacts updated at 1 of 11 sitesStudy arms: 1 to 3v10Show 1 more changeShow less
Study arms: 1 to 3
MinorRe-verified, no change to tracked fieldsv9
MinorSite details revised at 4 of 11 sitesv8
MinorStudy sites: 9 to 11v7
MinorStudy sites: 8 to 9v6
MinorStudy sites: 7 to 8v5
NotablePrimary and study completion dates: Nov 9, 2020 to Jul 17, 2023Study sites: 2 to 7 · Start date: Jan 15, 2018 to Dec 28, 2017v4Show 2 more changesShow less
Study sites: 2 to 7
Start date: Jan 15, 2018 to Dec 28, 2017
NotableTrial status: Not Yet Recruiting to RecruitingPrimary and study completion dates: Dec 16, 2022 to Nov 9, 2020 · Study sites: 0 to 2 · Start date changed from estimate of Feb 3, 2018 to Jan 15, 2018v3Show 3 more changesShow less
Primary and study completion dates: Dec 16, 2022 to Nov 9, 2020
Study sites: 0 to 2
Start date changed from estimate of Feb 3, 2018 to Jan 15, 2018
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.